Showing results (51-60 of 108) with videos related to
Sort By:
Pageof 11
Diagnostic Cytopathology|July 9, 2015
ALK and ROS1 rearrangements tested by fluorescence in situ hybridization in cytological smears from advanced non-small cell lung cancer patientsCecilia Bozzetti, Rita Nizzoli, Marcello Tiseo, et al.Cancers|August 27, 2021
Preliminary Report on Computed Tomography Radiomics Features as Biomarkers to Immunotherapy Selection in Lung Adenocarcinoma PatientsVincenza Granata, Roberta Fusco, Matilde Costa, et al.Current Oncology (Toronto, Ont.)|February 25, 2025
Perioperative Chemo-Immunotherapy in Non-Oncogene-Addicted Resectable Non-Small Cell Lung Cancer (NSCLC): Italian Expert Panel MeetingFilippo de Marinis, Andrea Ardizzoni, Ilaria Attili, et al.Cancer|July 2, 2003
Gemcitabine and cisplatin as induction chemotherapy for patients with unresectable Stage IIIA-bulky N2 and Stage IIIB nonsmall cell lung carcinoma: an Italian Lung Cancer Project Observational StudyFederico Cappuzzo, Giovanni Selvaggi, Vanesa Gregorc, et al.Anti-Cancer Agents in Medicinal Chemistry|July 28, 2021
Pembrolizumab for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer: Analysis of Prognostic Factors of OutcomesCarmelo Tibaldi, Francesca Mazzoni, Vieri Scotti, et al.Future Oncology (London, England)|March 22, 2023
Combi-TED: a new trial testing Tedopi<sup>®</sup> with docetaxel or nivolumab in metastatic non-small-cell lung cancer progressing after first lineLorenza Landi, Angelo Delmonte, Andrea Bonetti, et al.Journal for Immunotherapy of Cancer|May 9, 2025
Carboplatin, etoposide, atezolizumab, and bevacizumab in the first-line treatment of patients with extensive stage small-cell lung cancer: the GOIRC-01-2019 CeLEBrATE studyGiuseppe Lamberti, Karim Rihawi, Francesca Mazzoni, et al.Frontiers in Oncology|December 1, 2022
KRAS G12 isoforms exert influence over up-front treatments: A retrospective, multicenter, Italian analysis of the impact of first-line immune checkpoint inhibitors in an NSCLC real-life populationSara Fancelli, Enrico Caliman, Francesca Mazzoni, et al.JTO Clinical and Research Reports|November 24, 2025
Crizotinib in Patients With <i>ROS1</i>-Positive NSCLC With or Without Brain Metastases: Post Hoc Analysis of Phase II METROS TrialLorenza Landi, Rita Chiari, Marcello Tiseo, et al.Life (Basel, Switzerland)|August 26, 2022
Immune-Checkpoint-Inhibitor-Related Lung Toxicity: A Multicentre Real-Life Retrospective Portrait from Six Italian CentresPaolo Cameli, Paola Faverio, Katia Ferrari, et al.Pageof 11